National Psoriasis Foundation MY STUDIES | JANUARY 2015 Having trouble? View as web page National Psoriasis Foundation longo My Studies is a monthly newsletter featuring the latest psoriasis and psoriatic arthritis research study, survey and clinical trial opportunities in your area. You can play an important role in advancing the pace of psoriatic disease research by participating in studies and trials. In fact, your direct participation may lead to the development of better, safer, more effective treatments for over 7.5 million Americans living with psoriasis and an estimated 2 million living with psoriatic arthritis. Studies near you: Have you been diagnosed with plaque-type psoriasis, but still experience symptoms despite treatment? Participating in a new clinical research study of a biologic treatment may be the right approach for you! An investigational medication is being tested that could improve your symptoms in a similar way to an approved treatment for plaque-type psoriasis. All patients participating in the study will receive the investigational medication and/or Humira®, an existing treatment for plaque-type psoriasis. Applicants must be at least 18 years old, have a diagnosis of chronic plaque-type psoriasis for at least 6 months with ongoing moderate-to-severe symptoms and no history of tuberculosis (TB). Click here for more information » Researchers at Baylor University Medical Center are trying to determine to what extent providers discuss with their patients disorders associated with psoriasis and how well patients understand them. If you have EVER been diagnosed with psoriasis by a doctor, please take several minutes to complete this confidential web-based survey. Your responses are very important and may help providers better care for patients with psoriasis. Thank you! If you have previously completed this short survey, please do so one more time as the previous data was not recorded. Click here for more information » Study of Efficacy and Safety of Brodalumab in Subjects With Psoriatic Arthritis (AMVISION-2) The primary objective of this study is to evaluate the efficacy of brodalumab, compared to placebo, in subjects with psoriatic arthritis. The key secondary objective is to evaluate the efficacy of brodalumab compared to placebo at week 16. The safety objective of this study is to evaluate the safety profile of brodalumab in subjects with psoriatic arthritis. Click here for more information » This email was sent by: National Psoriasis Foundation 6600 SW 92nd Avenue, Suite 300 Portland, OR, 97223, USA Manage your e-mail subscriptions: Edit your profile and preferences. | Unsubscribe from all e-newsletters. | Unsubscribe from this e-newsletter.
Posted on: Thu, 08 Jan 2015 19:43:42 +0000
Trending Topics
Recently Viewed Topics
© 2015